Want to see ORGO full AI Analyst Report?
ORGO Stock Chart & Stats
$1.74
$0.13(5.44%)
At close: 4:00 PM EDT
$1.74
$0.13(5.44%)
Day’s Range― - ―
52-Week Range$1.36 - $7.08
Previous CloseN/A
Volume86.56K
Average Volume (3M)824.85K
Market Cap
$187.86M
Enterprise Value$472.65
Total Cash (Recent Filing)$46.10M
Total Debt (Recent Filing)$66.95M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding128,674,550
10 Day Avg. Volume651,212
30 Day Avg. Volume824,848
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.17
P/FCF Ratio-26.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.00Price Target Upside14.94% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.38
Revenue Forecast (FY)$196.05M
Bulls Say, Bears Say
Bulls Say
Clinical EvidencePositive randomized-trial results and large real-world Medicare evidence strengthen the clinical case for Organogenesis products. This can support physician adoption, payer discussions, and durable utilization in difficult-to-treat wound populations over the coming quarters.
Cost RestructuringThe restructuring program provides a measurable path to a lower operating cost base, with savings already visible in non-GAAP expenses. If execution continues, reduced overhead can improve operating leverage and help the company recover profitability as revenue stabilizes.
Debt-Free Balance SheetHaving no outstanding debt reduces mandatory financing costs and gives management greater flexibility while the business restructures. The stated 12-month funding expectation provides time to execute cost actions, support product sales, and pursue clinical or regulatory milestones.
Bears Say
Revenue ContractionThe steep decline in product revenue indicates a major contraction in current demand and commercial activity, not merely slower growth. Sustained weakness would reduce operating leverage, pressure cash generation, and make the recovery dependent on a substantial rebound in later periods.
Margin And Earnings DeteriorationSharp gross-margin compression alongside a much wider net loss shows that lower revenue is damaging profitability disproportionately. Even with cost reductions, restoring earnings power may take time if product mix, utilization, or restructuring-related costs continue to weigh on margins.
Delayed Product RevenuePushing the Dermagraft launch back by roughly a year delays a potential source of commercial growth and extends reliance on the existing portfolio. The decision preserves cash near term but also postpones diversification and the opportunity to rebuild revenue sooner.
Organogenesis Holdings News
ORGO FAQ
What was Organogenesis Holdings Inc’s price range in the past 12 months?
Organogenesis Holdings Inc lowest stock price was $1.35 and its highest was $7.08 in the past 12 months.
What is Organogenesis Holdings Inc’s market cap?
Organogenesis Holdings Inc’s market cap is $187.86M.
When is Organogenesis Holdings Inc’s upcoming earnings report date?
Organogenesis Holdings Inc’s upcoming earnings report date is Nov 05, 2026 which is in 48 days.
How were Organogenesis Holdings Inc’s earnings last quarter?
Organogenesis Holdings Inc released its earnings results on Aug 06, 2026. The company reported -$0.714 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.364.
Is Organogenesis Holdings Inc overvalued?
According to Wall Street analysts Organogenesis Holdings Inc’s price is currently Undervalued.
Does Organogenesis Holdings Inc pay dividends?
Organogenesis Holdings Inc does not currently pay dividends.
What is Organogenesis Holdings Inc’s EPS estimate?
Organogenesis Holdings Inc’s EPS estimate is -0.18.
How many shares outstanding does Organogenesis Holdings Inc have?
Organogenesis Holdings Inc has 128,674,550 shares outstanding.
What happened to Organogenesis Holdings Inc’s price movement after its last earnings report?
Organogenesis Holdings Inc reported an EPS of -$0.714 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went down -22.822%.
Which hedge fund is a major shareholder of Organogenesis Holdings Inc?
Currently, no hedge funds are holding shares in ORGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organogenesis Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (14.94% Upside)
$2.00 (14.94% Upside)
Blogger Sentiment
Bullish
ORGO Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 13.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Organogenesis Holdings Inc
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
ORGO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented meaningful operational and clinical positives — sequential revenue recovery, strong clinical trial results (PuraPly AM and Affinity), FDA acceptance of the Amnuvx BLA and tangible cost-reduction measures — but these are outweighed by significant near-term financial stress: severe year-over-year revenue declines (≈58%), large operating and GAAP net losses, a halved cash position since year-end, lowered full-year revenue guidance, and deferred product launch timing to preserve cash. Management is focused on evidence-driven market share gains and expects improving adjusted EBITDA by Q4, but the company remains in a substantial recovery phase with execution and financing risks in the near term.View all ORGO earnings summariesORGO Stock 12 Month Forecast
Average Price Target
$2.00
▲(14.94% Upside)
Technical Analysis
Ownership Overview
17.00% Insiders
7.01% Mutual Funds
11.71% Other Institutional Investors
52.27% Public Companies and
Individual Investors